Skip to main content

Table 1 Patient information

From: Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer

Age (years) 66 (60–72)
Sex
 Female 12 (46%)
 Male 14 (54%)
Histology
 Adenocarcinoma 26 (100%)
Tumor location
 Head 21 (81%)
 Body 4 (15%)
 Tail 1 (4%)
Resectability status (at diagnosis)
 Borderline resectable 11 (42%)
 Locally advanced 15 (58%)
Induction chemotherapy
 FOLFRINOX 16 (62%)
 Gem/Abraxane 6 (23%)
  FOLFRINOX and Gem/Abraxane 4 (15%)
Time to progression (days) 120 (60–180)
Follow-up (days) 200 (111–289)
  1. Number quoted is the number of patients in each category for categorical variables, and median value for numerical variables, while the number in brackets signifies percentage of all patients in the category and 25th to 75th percentile range respectively. Follow-up time is quoted for patients who did not progress as time to censoring